Role of carbohydrate antigens sialyl Lewis (a) (CA19-9) in bronchoalveolar lavage in patients with pulmonary fibrosis

Respiration. 2000;67(2):146-52. doi: 10.1159/000029502.

Abstract

Background: It has been reported that carbohydrate antigen sialyl Lewis (a) (CA19-9) levels are elevated in serum as well as in bronchoalveolar lavage fluid (BALF) of patients with pulmonary fibrosis. However, the biological significance of CA19-9 is unclear.

Objective: The purpose of the present study was to evaluate correlations between CA19-9 levels in BALF and several biochemical as well as clinical parameters in patients with pulmonary fibrosis. In addition, biological functions of CA19-9 were also examined.

Methods: We studied 24 patients with a diagnosis of pulmonary fibrosis: 16 with idiopathic pulmonary fibrosis (IPF) and 8 with pulmonary fibrosis associated with a collagen vascular disorder (PF-CVD). In BALF, carbohydrate antigens sialyl Lewis (a) (CA19-9), elastase: alpha(1)-proteinase inhibitor complex (E-PI), hepatocyte growth factor (HGF), LDH, IgG, IgA, albumin, and cell differentiation were measured. We also evaluated the effects of CA19-9 on neutrophil functions.

Results: CA19-9/albumin levels in BALF significantly correlated with HGF/albumin, elastase/albumin, LDH/albumin, total number of alveolar macrophages, and total number of neutrophils. Purified CA19-9 had a chemotactic activity for neutrophils. In addition, neutrophil chemotactic activity to C5a, fMLP, and interleukin 8 was significantly stimulated after incubation with purified CA19-9. Furthermore, CA19-9 increased the expression of CD15s on neutrophils.

Conclusions: Our data demonstrated (i) CA19-9 in BALF correlated with other markers of inflammation in pulmonary fibrosis, and (ii) CA19-9 can modify neutrophil functions. These results suggest that CA19-9 may play a role in the process of lung injury in patients with pulmonary fibrosis.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Bronchoalveolar Lavage Fluid / chemistry*
  • Bronchoalveolar Lavage Fluid / cytology
  • Bronchoalveolar Lavage Fluid / immunology
  • CA-19-9 Antigen / metabolism*
  • CA-19-9 Antigen / pharmacology
  • Cell Differentiation
  • Chemotaxis, Leukocyte / drug effects
  • Chemotaxis, Leukocyte / immunology
  • Collagen Diseases / complications
  • Collagen Diseases / physiopathology*
  • Complement C5a / pharmacology
  • Dose-Response Relationship, Drug
  • Female
  • Hepatocyte Growth Factor / metabolism
  • Humans
  • Immunoglobulin A / metabolism
  • Immunoglobulin G / metabolism
  • Interleukin-8 / pharmacology
  • L-Lactate Dehydrogenase / metabolism
  • Leukocyte Elastase / metabolism
  • Lung Diseases, Interstitial / complications
  • Lung Diseases, Interstitial / physiopathology
  • Lymphocyte Activation / drug effects
  • Macrophages, Alveolar / drug effects
  • Macrophages, Alveolar / metabolism
  • Male
  • Middle Aged
  • N-Formylmethionine Leucyl-Phenylalanine / pharmacology
  • Neutrophils / cytology
  • Neutrophils / drug effects
  • Neutrophils / immunology
  • Neutrophils / metabolism
  • Pulmonary Fibrosis / complications
  • Pulmonary Fibrosis / physiopathology*
  • Serum Albumin / metabolism
  • alpha 1-Antitrypsin / metabolism

Substances

  • CA-19-9 Antigen
  • Immunoglobulin A
  • Immunoglobulin G
  • Interleukin-8
  • Serum Albumin
  • alpha 1-Antitrypsin
  • alpha 1-antitrypsin-leukocyte elastase complex
  • N-Formylmethionine Leucyl-Phenylalanine
  • Hepatocyte Growth Factor
  • Complement C5a
  • L-Lactate Dehydrogenase
  • Leukocyte Elastase